Abstract
Stem cell-based therapy is emerging as a promising strategy to treat end-stage heart failure, a leading cause of morbidity and mortality. Stem cells can be isolated from a variety of sources and exhibit unique characteristics that impact their potential therapeutic utility. The adult heart contains small populations of committed, multipotent cardiac stem cells (CSC), which are adapted to the cardiac microenvironment and participate in postnatal physiological and pathological cardiac renewal or repair. These cells can be isolated, expanded in culture, and administered therapeutically to improve cardiac function in the setting of heart failure. CSC can be differentiated into three distinct cardiovascular lineages and exhibit enhanced paracrine factor production and engraftment as compared with other types of mesenchymal stem cells, which in turn may translate into improved therapeutic efficacy. The cell surface marker expression and phenotype of these CSC, however, depends on the method of isolation, selection and propagation, which likely explains the variable experimental results obtained to date. Moreover, invasive procedures are required to obtain CSC from humans. Early trials using autologous CSC in patients with ischemic cardiomyopathy have demonstrated feasibility and safety, along with variable degrees of therapeutic efficacy in terms of enhancing myocardial viability and cardiac function. Further studies are needed to optimize methods of CSC isolation, manipulation and delivery. If fully realized, the potential of CSC therapy could fundamentally change the approach to the treatment of end-stage heart failure.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 294-300 |
| Number of pages | 7 |
| Journal | Experimental Biology and Medicine |
| Volume | 238 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 1 2013 |
| Externally published | Yes |
Fingerprint
Keywords
- Cardiac stem cells
- Cardiosphere
- Heart regeneration
- Hypoxic preconditioning
- MicroRNA
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)
Cite this
Cardiac-derived stem cell-based therapy for heart failure : Progress and clinical applications. / Tang, Yao Liang; Wang, Yingjie J.; Chen, Lijuan J.; Pan, Yaohua H.; Zhang, Lan; Weintraub, Neal Lee.
In: Experimental Biology and Medicine, Vol. 238, No. 3, 01.03.2013, p. 294-300.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cardiac-derived stem cell-based therapy for heart failure
T2 - Progress and clinical applications
AU - Tang, Yao Liang
AU - Wang, Yingjie J.
AU - Chen, Lijuan J.
AU - Pan, Yaohua H.
AU - Zhang, Lan
AU - Weintraub, Neal Lee
PY - 2013/3/1
Y1 - 2013/3/1
N2 - Stem cell-based therapy is emerging as a promising strategy to treat end-stage heart failure, a leading cause of morbidity and mortality. Stem cells can be isolated from a variety of sources and exhibit unique characteristics that impact their potential therapeutic utility. The adult heart contains small populations of committed, multipotent cardiac stem cells (CSC), which are adapted to the cardiac microenvironment and participate in postnatal physiological and pathological cardiac renewal or repair. These cells can be isolated, expanded in culture, and administered therapeutically to improve cardiac function in the setting of heart failure. CSC can be differentiated into three distinct cardiovascular lineages and exhibit enhanced paracrine factor production and engraftment as compared with other types of mesenchymal stem cells, which in turn may translate into improved therapeutic efficacy. The cell surface marker expression and phenotype of these CSC, however, depends on the method of isolation, selection and propagation, which likely explains the variable experimental results obtained to date. Moreover, invasive procedures are required to obtain CSC from humans. Early trials using autologous CSC in patients with ischemic cardiomyopathy have demonstrated feasibility and safety, along with variable degrees of therapeutic efficacy in terms of enhancing myocardial viability and cardiac function. Further studies are needed to optimize methods of CSC isolation, manipulation and delivery. If fully realized, the potential of CSC therapy could fundamentally change the approach to the treatment of end-stage heart failure.
AB - Stem cell-based therapy is emerging as a promising strategy to treat end-stage heart failure, a leading cause of morbidity and mortality. Stem cells can be isolated from a variety of sources and exhibit unique characteristics that impact their potential therapeutic utility. The adult heart contains small populations of committed, multipotent cardiac stem cells (CSC), which are adapted to the cardiac microenvironment and participate in postnatal physiological and pathological cardiac renewal or repair. These cells can be isolated, expanded in culture, and administered therapeutically to improve cardiac function in the setting of heart failure. CSC can be differentiated into three distinct cardiovascular lineages and exhibit enhanced paracrine factor production and engraftment as compared with other types of mesenchymal stem cells, which in turn may translate into improved therapeutic efficacy. The cell surface marker expression and phenotype of these CSC, however, depends on the method of isolation, selection and propagation, which likely explains the variable experimental results obtained to date. Moreover, invasive procedures are required to obtain CSC from humans. Early trials using autologous CSC in patients with ischemic cardiomyopathy have demonstrated feasibility and safety, along with variable degrees of therapeutic efficacy in terms of enhancing myocardial viability and cardiac function. Further studies are needed to optimize methods of CSC isolation, manipulation and delivery. If fully realized, the potential of CSC therapy could fundamentally change the approach to the treatment of end-stage heart failure.
KW - Cardiac stem cells
KW - Cardiosphere
KW - Heart regeneration
KW - Hypoxic preconditioning
KW - MicroRNA
UR - http://www.scopus.com/inward/record.url?scp=84877642162&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84877642162&partnerID=8YFLogxK
U2 - 10.1177/1535370213477982
DO - 10.1177/1535370213477982
M3 - Article
VL - 238
SP - 294
EP - 300
JO - Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)
JF - Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N. Y.)
SN - 1535-3702
IS - 3
ER -